Drugs / DN022150
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07656376 | Jun 2027 → Feb 2029 expected | exocrine pancreatic carcinoma | Jiangxi Kvvit Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07689539 | Sep 2026 → Jul 2028 expected | malignant pancreatic neoplasm | Jiangxi Kvvit Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DN022150 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07656376 ↗ |
| Route | Intravenous | “iv QW 28-day/cycle” NCT07689539 ↗ |